ToxSci Advance Access originally published online on March 3, 2007
Toxicological Sciences 2007 97(1):27-31; doi:10.1093/toxsci/kfm020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Utility of an International Sera Bank for Use in Evaluating the Potential Human Allergenicity of Novel Proteins
* International Life Sciences Institute Health and Environmental Sciences Institute, Washington, District of Columbia 20005
Monsanto Co., 800 North Lindbergh Boulevard, St Louis, Missouri 63167
Bayer CropScience, 355 rue Doistoïevski, 06903 Sophia Antipolis Cedex, France
Dupont Company, E400/4402, Route 141 and Henry Clay Road, Wilmington, Delaware 19880-0400
¶ Pediatric Allergy and Immunology, Duke University Medical Center, Durham, North Carolina 27710
|| Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Ilwon-dong, Kangnam-Ku, Seoul 135-710, Korea
||| BASF Plant Science, 26 Davis Drive, Research Triangle Park, North Carolina 27709
|||| Allergy Unit, Department of Dermatology, University Hospital Zürich, Switzerland
# Division of Allergology, Paul-Ehrlich-Institut, Paul-Ehrlich-Strasse 51-59, D-63225 Langen, Germany
1 To whom correspondence should be addressed at International Life Sciences Institute Health and Environmental Sciences Institute, One Thomas Circle NW, Ninth Floor, Washington, District of Columbia 20005. Fax: (202) 659-33617. E-mail: kthomas{at}ilsi.org.
Received February 8, 2007; accepted February 12, 2007
 |
Abstract |
|---|
In the safety assessment of novel foods produced through biotechnology, careful consideration is given to determining the allergenic potential of newly introduced proteins. IgE serum screening is one tool for evaluating whether the protein in question has sequence identity to a known allergen or if the source of the gene encoding the protein is a known allergenic food. A "specific" serum screen involves testing a gene product with sera from patients with documented clinical allergy to a specific allergen to confirm that the gene product of interest is not the same protein to which the patient produces IgE antibodies. A "targeted" serum screen involves testing the gene product of interest with sera from patients sensitive to food or aeroallergens from the same broad group. The concept of a global sera bank with accessible, well-characterized sera for use in such assays is an appealing option. This paper summarizes the consensus elements from a workshop to evaluate the potential utility of an international sera bank for evaluating the allergenicity of novel proteins. Areas of agreement following the workshop included the following: (1) specific sera screens are appropriate for exploring potentially cross-reactive proteins that have been identified through bioinformatics analyses; however, additional validation is needed, particularly for targeted sera screens, (2) practical and ethical considerations may preclude the formation of a global sera bank, and therefore, (3) a regional network of clinicians who could serve as sources of patient sera or be approached to conduct sera studies would be the most practical alternative.
Key Words: sera bank; allergenicity; serum screening; atopic diseases.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. K. Selgrade, C. C. Bowman, G. S. Ladics, L. Privalle, and S. A. Laessig Safety Assessment of Biotechnology Products for Potential Risk of Food Allergy: Implications of New Research Toxicol. Sci., July 1, 2009; 110(1): 31 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Croft Jr, R. M. Jordan, H. L. Patney, C. D. Shriver, M. N. Vernalis, T. J. Orchard, and D. L. Ellsworth Performance of Whole-Genome Amplified DNA Isolated from Serum and Plasma on High-Density Single Nucleotide Polymorphism Arrays J. Mol. Diagn., May 1, 2008; 10(3): 249 - 257. [Abstract] [Full Text] [PDF]
|
|